CD34 Chimerism Directed Donor Lymphocyte Infusion With or Without Azacitidine Results in Reduced Relapse and Superior Overall Survival When Full Donor Chimerism is Achieved in Allogeneic Stem Cell Transplant Recipients With Acute Myeloid Leukaemia/Myelodysplastic Syndrome
Clinical Lymphoma Myeloma and Leukemia · 2024-11 · 24 (11) · e852-e860
DOI: 10.1016/j.clml.2024.07.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024-11. Verfasst von Joanne Lc Tan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Malignant Haematology, Transplantation and Cellular Therapies, The Alfred Hospital, Victoria, Australia. Electronic address: joa.tan@al…. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphocyte Transfusion, Azacitidine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Regular monitoring of CD34 donor chimerism (DC) is a highly sensitive method of predicting relapse in allogeneic stem cell transplant (alloHSCT) recipients with AML/MDS. A fall of CD34 DC below 80% is an indicator of ensuing relapse. There are limited studies assessing the efficacy of donor lymphocyte infusion (DLI) triggered by mixed CD34 DC (MDC), in addressing falling chimerism. PATIENTS AND METHODS: We performed a retrospective analysis of consecutive alloHSCT patients between 2012 to 2023 who received DLI (with or without azacitidine) for CD34 MDC without morphologic relapse at the time of infusion. RESULTS: Of the 21 patients with follow up CD34 DC available, 14 (66.7%) achieved CD34 full donor chimerism (FDC) following DLI with or without azacitidine (dli-FDC), while 7 (33.3%) did not (dli-MDC). The 2-year cumulative incidence of relapse (CIR) was significantly lower in dli-FDC compared to dli-MDC (21.4% vs. 85.7%, P < 0.001), correlating with superior overall survival (OS; median years not reached vs. 0.67 years [95% CI, 0.58-ND], P < .001). Rates of grade II-IV acute GVHD post-DLI were 14.9%, and moderate-severe cGVHD was 42.8% in the dli-FDC group. The 5-year nonrelapse mortality (NRM) of the dli-FDC group was 7.1% following DLI. CONCLUSION: Our study shows the restoration of CD34 FDC post-DLI is associated with reduced relapse and improved overall survival, with low NRM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Malignant Haematology, Transplantation and Cellular Therapies, The Alfred Hospital, Victoria, Australia. Electronic address: joa.tan@alfred.org.au.
- Department of Malignant Haematology, Transplantation and Cellular Therapies, The Alfred Hospital, Victoria, Australia.
Zitieren
APA
Tan, J. L., Curtis, D. J., Muirhead, J., Swain, M. I., Fleming, S. A., Cirone, B., O'Brien, M. E., Wong, S. M., Inam, S., Patil, S., & Spencer, A. (2024). CD34 Chimerism Directed Donor Lymphocyte Infusion With or Without Azacitidine Results in Reduced Relapse and Superior Overall Survival When Full Donor Chimerism is Achieved in Allogeneic Stem Cell Transplant Recipients With Acute Myeloid Leukaemia/Myelodysplastic Syndrome. Clinical Lymphoma Myeloma and Leukemia, 24(11), e852-e860. https://doi.org/10.1016/j.clml.2024.07.006
Vancouver
Tan JL, Curtis DJ, Muirhead J, Swain MI, Fleming SA, Cirone B, et al. CD34 Chimerism Directed Donor Lymphocyte Infusion With or Without Azacitidine Results in Reduced Relapse and Superior Overall Survival When Full Donor Chimerism is Achieved in Allogeneic Stem Cell Transplant Recipients With Acute Myeloid Leukaemia/Myelodysplastic Syndrome. Clinical Lymphoma Myeloma and Leukemia. 2024;24(11):e852-e860. doi:10.1016/j.clml.2024.07.006
BibTeX
@article{Tan2024,
author = {Tan, Joanne Lc and Curtis, David J and Muirhead, Jenny and Swain, Michael I and Fleming, Shaun A and Cirone, Bianca and O'Brien, Maureen E and Wong, Shu M and Inam, Shafqat and Patil, Sushrut and Spencer, Andrew},
title = {CD34 Chimerism Directed Donor Lymphocyte Infusion With or Without Azacitidine Results in Reduced Relapse and Superior Overall Survival When Full Donor Chimerism is Achieved in Allogeneic Stem Cell Transplant Recipients With Acute Myeloid Leukaemia/Myelodysplastic Syndrome},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2024},
volume = {24},
number = {11},
pages = {e852--e860},
doi = {10.1016/j.clml.2024.07.006}
}
EUVIMED